Table 3.
Demographic and clinical characteristics of the asthmatic subjects included in the study
| Age, years (mean ± SD/range) | 54 ± 11.3/36–70 |
|---|---|
| Sex (male/female | 6/6 |
| Smokers/former smokers | 0/0 |
| Atopy - number (%) of patients | 5 (41.6) |
| FEV1/FVC | 64.0 ± 10.7 |
| Post-bronchodilator FEV1 - % predicted (mean ± SD) | 77.4 ± 14.7 |
| Inhaled corticosteroids (as mcg of beclomethasone or equivalent – range) | 1000–2000 |
| Inhaled LABA (as mcg of salmeterol or equivalent – range) | 200–400 |
| Chronic oral corticosteroid use (no - % of patients) | 7–58% |
| Daily dose of oral corticosteroids (mg of prednisone or equivalent) | 21.2 ± 13.8 |
| Intermittent oral corticosteroids (< 6 months/year) (no - % of patients) | 5–42% |
| Previous treatment with omalizumab - number (%) of patients | 5 (41.6%) |
| AQLQ score at baseline (mean ± SD), 0–4 point scale | 2.9 ± 0.9 |
| ACQ score at baseline (mean ± SD), 0–7 point scale | 4.7 ± 0,8 |
| Exacerbation/patient/year (12 months before recruitment) | 4.7 ± 2.0 |
| Hospitalizations/patient/year (12 months before recruitment) | 1.2 ± 1.7 |
| Days lost of work/patient/year (12 months before recruitment) | 27.2 ± 21.3 |